PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER...

PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA)

McGovern, I., Simon, A., Shirali, R., Zhong, Y., Perini, R., Lorenzi, M., Adejoro, O.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.242
Date:
November, 2019
File:
PDF, 381 KB
2019
Conversion to is in progress
Conversion to is failed